Cargando…

Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial

BACKGROUND: A clinical pattern of damage to the auditory, visual, and vestibular sensorimotor systems, known as multi-sensory impairment, affects roughly 2% of the US population each year. Within the population of US military service members exposed to mild traumatic brain injury (mTBI), 15–44% will...

Descripción completa

Detalles Bibliográficos
Autores principales: Ervin, Ann-Margret, Schubert, Michael C., Migliaccio, Americo A., Perin, Jamie, Coulibaly, Hamadou, Millar, Jennifer L., Roberts, Dale, Shelhamer, Mark, Gold, Daniel, Beauregard, Stephanie, Pinto, Robin, Brungart, Douglas, Ward, Bryan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666079/
https://www.ncbi.nlm.nih.gov/pubmed/34895314
http://dx.doi.org/10.1186/s13063-021-05876-4
_version_ 1784614136547639296
author Ervin, Ann-Margret
Schubert, Michael C.
Migliaccio, Americo A.
Perin, Jamie
Coulibaly, Hamadou
Millar, Jennifer L.
Roberts, Dale
Shelhamer, Mark
Gold, Daniel
Beauregard, Stephanie
Pinto, Robin
Brungart, Douglas
Ward, Bryan K.
author_facet Ervin, Ann-Margret
Schubert, Michael C.
Migliaccio, Americo A.
Perin, Jamie
Coulibaly, Hamadou
Millar, Jennifer L.
Roberts, Dale
Shelhamer, Mark
Gold, Daniel
Beauregard, Stephanie
Pinto, Robin
Brungart, Douglas
Ward, Bryan K.
author_sort Ervin, Ann-Margret
collection PubMed
description BACKGROUND: A clinical pattern of damage to the auditory, visual, and vestibular sensorimotor systems, known as multi-sensory impairment, affects roughly 2% of the US population each year. Within the population of US military service members exposed to mild traumatic brain injury (mTBI), 15–44% will develop multi-sensory impairment following a mild traumatic brain injury. In the US civilian population, multi-sensory impairment-related symptoms are also a common sequela of damage to the vestibular system and affect ~ 300–500/100,000 population. Vestibular rehabilitation is recognized as a critical component of the management of multi-sensory impairment. Unfortunately, the current clinical practice guidelines for the delivery of vestibular rehabilitation are not evidence-based and primarily rely on expert opinion. The focus of this trial is gaze stability training, which represents the unique component of vestibular rehabilitation. The aim of the Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) trial is to assess the efficacy of a non-invasive, incremental vestibular adaptation training device for normalizing the response of the vestibulo-ocular reflex. METHODS: The INVENT VPT Trial is a multi-center randomized controlled crossover trial in which military service members with mTBI and civilian patients with vestibular hypofunction are randomized to begin traditional vestibular rehabilitation or incremental vestibular adaptation and then cross over to the alternate intervention after a prescribed washout period. Vestibulo-ocular reflex function and other functional outcomes are measured to identify the best means to improve the delivery of vestibular rehabilitation. We incorporate ecologically valid outcome measures that address the common symptoms experienced in those with vestibular pathology and multi-sensory impairment. DISCUSSION: The INVENT VPT Trial will directly impact the health care delivery of vestibular rehabilitation in patients suffering from multi-sensory impairment in three critical ways: (1) compare optimized traditional methods of vestibular rehabilitation to a novel device that is hypothesized to improve vestibulo-ocular reflex performance, (2) isolate the ideal dosing of vestibular rehabilitation considering patient burden and compliance rates, and (3) examine whether recovery of the vestibulo-ocular reflex can be predicted in participants with vestibular symptoms. TRIAL REGISTRATION: ClinicalTrials.gov NCT03846830. Registered on 20 February 2019.
format Online
Article
Text
id pubmed-8666079
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86660792021-12-13 Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial Ervin, Ann-Margret Schubert, Michael C. Migliaccio, Americo A. Perin, Jamie Coulibaly, Hamadou Millar, Jennifer L. Roberts, Dale Shelhamer, Mark Gold, Daniel Beauregard, Stephanie Pinto, Robin Brungart, Douglas Ward, Bryan K. Trials Study Protocol BACKGROUND: A clinical pattern of damage to the auditory, visual, and vestibular sensorimotor systems, known as multi-sensory impairment, affects roughly 2% of the US population each year. Within the population of US military service members exposed to mild traumatic brain injury (mTBI), 15–44% will develop multi-sensory impairment following a mild traumatic brain injury. In the US civilian population, multi-sensory impairment-related symptoms are also a common sequela of damage to the vestibular system and affect ~ 300–500/100,000 population. Vestibular rehabilitation is recognized as a critical component of the management of multi-sensory impairment. Unfortunately, the current clinical practice guidelines for the delivery of vestibular rehabilitation are not evidence-based and primarily rely on expert opinion. The focus of this trial is gaze stability training, which represents the unique component of vestibular rehabilitation. The aim of the Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) trial is to assess the efficacy of a non-invasive, incremental vestibular adaptation training device for normalizing the response of the vestibulo-ocular reflex. METHODS: The INVENT VPT Trial is a multi-center randomized controlled crossover trial in which military service members with mTBI and civilian patients with vestibular hypofunction are randomized to begin traditional vestibular rehabilitation or incremental vestibular adaptation and then cross over to the alternate intervention after a prescribed washout period. Vestibulo-ocular reflex function and other functional outcomes are measured to identify the best means to improve the delivery of vestibular rehabilitation. We incorporate ecologically valid outcome measures that address the common symptoms experienced in those with vestibular pathology and multi-sensory impairment. DISCUSSION: The INVENT VPT Trial will directly impact the health care delivery of vestibular rehabilitation in patients suffering from multi-sensory impairment in three critical ways: (1) compare optimized traditional methods of vestibular rehabilitation to a novel device that is hypothesized to improve vestibulo-ocular reflex performance, (2) isolate the ideal dosing of vestibular rehabilitation considering patient burden and compliance rates, and (3) examine whether recovery of the vestibulo-ocular reflex can be predicted in participants with vestibular symptoms. TRIAL REGISTRATION: ClinicalTrials.gov NCT03846830. Registered on 20 February 2019. BioMed Central 2021-12-11 /pmc/articles/PMC8666079/ /pubmed/34895314 http://dx.doi.org/10.1186/s13063-021-05876-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Ervin, Ann-Margret
Schubert, Michael C.
Migliaccio, Americo A.
Perin, Jamie
Coulibaly, Hamadou
Millar, Jennifer L.
Roberts, Dale
Shelhamer, Mark
Gold, Daniel
Beauregard, Stephanie
Pinto, Robin
Brungart, Douglas
Ward, Bryan K.
Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title_full Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title_fullStr Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title_full_unstemmed Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title_short Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation (INVENT VPT) Trial: study protocol for a randomized controlled crossover trial
title_sort incremental velocity error as a new treatment in vestibular rehabilitation (invent vpt) trial: study protocol for a randomized controlled crossover trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666079/
https://www.ncbi.nlm.nih.gov/pubmed/34895314
http://dx.doi.org/10.1186/s13063-021-05876-4
work_keys_str_mv AT ervinannmargret incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT schubertmichaelc incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT migliaccioamericoa incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT perinjamie incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT coulibalyhamadou incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT millarjenniferl incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT robertsdale incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT shelhamermark incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT golddaniel incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT beauregardstephanie incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT pintorobin incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT brungartdouglas incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT wardbryank incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial
AT incrementalvelocityerrorasanewtreatmentinvestibularrehabilitationinventvpttrialstudyprotocolforarandomizedcontrolledcrossovertrial